Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00673257 · ClinicalTrials.gov registry record · NA

Pharmacokinetics of Daunorubicin in Young Patients With Cancer

A NA study of Unspecified Childhood Solid Tumor, Protocol Specific, sponsored by Children's Oncology Group.

Completed
Registry status
NA
Development phase
107
Enrollment target
20
Study locations

NCT00673257: Completed NA study of Unspecified Childhood Solid Tumor, Protocol Specific, sponsored by Children's Oncology Group.

NCT00673257 is a NA study of Unspecified Childhood Solid Tumor, Protocol Specific that has completed, run by Children's Oncology Group. The registered enrollment target is 107 participants, below the 1,629-participant average among 13 other Unspecified Childhood Solid Tumor, Protocol Specific trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00673257, a NA study of Unspecified Childhood Solid Tumor, Protocol Specific, has completed, sponsored by Children's Oncology Group.

COMPLETED
Registry status
NA
Development phase
107 participants
Enrollment target
20
Study locations

Study Summary

This laboratory study is looking at the pharmacokinetics of daunorubicin in young patients with cancer. Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about how patients respond to treatment with certain chemotherapy drugs.

Primary Outcome

Pharmacokinetic parameters of Daunorubicin hydrochloride will be analyzed, samples were drawn according to the following schedule: prior to the drug infusion, at the midpoint of the infusion if infusion is ≥ 30 min in duration, end of infusion and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (when feasible) hours after the end of the infusion. Samples will also be collected at 24, 48, and 72 (when feasible) hours after the end of the infusion. The concentration time data will be analyzed by model dependen

Interventions

  • OTHER pharmacological study
  • PROCEDURE dual x-ray absorptimetry

Study Locations (20)

Florida

  • Lee Cancer Care of Lee Memorial Health System - Fort Myers
  • Nemours Children's Clinic - Jacksonville
  • Sacred Heart Cancer Center at Sacred Heart Hospital - Pensacola
  • All Children's Hospital - St. Petersburg
  • St. Joseph's Cancer Institute at St. Joseph's Hospital - Tampa

California

  • Childrens Hospital Los Angeles - Los Angeles
  • Children's Hospital of Orange County - Orange
  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
  • Stanford Cancer Center - Stanford

Georgia

  • Winship Cancer Institute of Emory University - Atlanta
  • MBCCOP - Medical College of Georgia Cancer Center - Augusta

Illinois

  • Children's Memorial Hospital - Chicago - Chicago
  • Advocate Christ Medical Center - Oak Lawn

Kentucky

  • Lucille P. Markey Cancer Center at University of Kentucky - Lexington
  • Kosair Children's Hospital - Louisville

Alabama

  • UAB Comprehensive Cancer Center - Birmingham

Arizona

  • Phoenix Children's Hospital - Phoenix

Delaware

  • Alfred I. duPont Hospital for Children - Wilmington

Trial Details

FieldValue
Enrollment Target 107 participants
Start Date 2007-01
Est. Completion 2020-03-31
Phase NA
Children's Oncology Group

342 total trials

What the finished NCT00673257 record still lists

NCT00673257 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, below the 1,629-participant average among 13 other Unspecified Childhood Solid Tumor, Protocol Specific trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Unspecified Childhood Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 2 interventions - of which pharmacological study is the first listed.

NCT00673257 names 20 study sites across 10 states, led by Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT00673257 about?

NCT00673257 is a clinical study titled "Pharmacokinetics of Daunorubicin in Young Patients With Cancer". This laboratory study is looking at the pharmacokinetics of daunorubicin in young patients with cancer. Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about how patients respond to treatment with certain chemotherapy drugs.

What is the current status of trial NCT00673257?

This trial is currently completed. It is a NA study. The enrollment target is 107 participants. The study started on 2007-01. Estimated completion is 2020-03-31.

What conditions does trial NCT00673257 study?

This clinical trial studies the following conditions: Unspecified Childhood Solid Tumor, Protocol Specific.

What interventions are being tested in trial NCT00673257?

The interventions under investigation include: pharmacological study (OTHER), dual x-ray absorptimetry (PROCEDURE).

Who is sponsoring clinical trial NCT00673257?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00673257 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Unspecified Childhood Solid Tumor, Protocol Specific

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00673257's enrollment target sits among peer trials

107 5th of 13 higher than 9 of 13 other Unspecified Childhood Solid Tumor, Protocol Specific trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Unspecified Childhood Solid Tumor, Protocol Specific trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05491668 · 107 participants

    Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI

  • NCT06041594 · 107 participants · NA

    Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)

  • NCT06081426 · 107 participants · NA

    Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)

  • NCT06527599 · 107 participants · NA

    Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00673257, the US trial registry maintained by the National Library of Medicine. NCT00673257 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.